



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 15/12, 19/044, A61K 31/70		A1	(11) International Publication Number: WO 94/11381
			(43) International Publication Date: 26 May 1994 (26.05.94)

(21) International Application Number: PCT/US93/10134 (22) International Filing Date: 28 October 1993 (28.10.93) (30) Priority data: 07/975,700 13 November 1992 (13.11.92) US (71) Applicant: GREENWICH PHARMACEUTICALS INCORPORATED [US/US]; 501 Office Center Drive, Ft. Washington, PA 10934-3210 (US). (72) Inventors: AKHTAR, M., Nayeem ; 225 Chatham Place, Lansdale, PA 19446 (US). THOMSON, David, S. ; 602 Wick Lane, Bluebell, PA 19422 (US). ARORA, Sudershan, K. ; 279 Bradford Lane, Lansdale, PA 19446 (US).	(74) Agents: TURNER, John, B. et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, 1300 I Street, N.W., Washington, DC 20005-3315 (US). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.
--	---

(54) Title: ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS: DERIVATIVES OF PENTOSE MONOSACCHARIDES

(I)

(a)

(b)

(57) Abstract

Compounds of this invention are derivatives of pentose monosaccharides which exhibit anti-proliferative and anti-inflammatory activity as well as intermediates for the synthesis of these compounds. Methods of preparation, pharmaceutical compositions containing the compounds and methods of treating inflammatory and/or autoimmune disorders employing the compounds are disclosed. In formula (I) R¹ is C₅-C₁₅ alkyl; R² is NHR, NH(CH₂)_mCH(Q)(CH₂)_pNR'R'', or O(CH₂)_mCH(Q)(CH₂)_pNR'R'', wherein R is C₃-C₈ alkyl, C₃-C₈ hydroxyalkyl, cyclohexyl-C₁-C₅-alkyl, phenyl-C₂-C₅-alkyl or pyridinyl-C₁-C₅-alkyl, Q is H, CH₃, or C₂H₅, and m is from 1-4 and p is from 0-4 or Q is OH and m and p are from 1-3, R' and R'' are each H or a lower alkyl group or, together with the nitrogen atom carrying them, form a saturated heterocyclic substituent of formula (a) where X is CH₂, NH or O, and n ranges from 3-6; or R² is a saturated heterocyclic ring of formula (b) where X is CH₂, NH or O, and n is from 3-6; and R³ and R⁴ together form an acetal protecting group, or a physiologically acceptable salt thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY COMPOUNDS:
DERIVATIVES OF PENTOSE MONOSACCHARIDES

Field of the Invention

This invention relates to derivatives of pentose monosaccharides which exhibit anti-proliferative and anti-inflammatory activity as well as intermediate for the synthesis of these compounds. Compounds of the invention are useful for treating mammals with inflammatory and/or autoimmune disorders. This invention also relates to pharmaceutical compositions containing the disclosed compounds and to methods of treating inflammatory and/or autoimmune disorders employing the disclosed compounds.

Description of the Related Art

Certain monosaccharides and their derivatives are known to have therapeutic value in the treatment of inflammatory and autoimmune disorders. Monosaccharides, particularly the pentoses and hexoses, are well known compounds. Synthesis of derivatives of these sugars can generally be accomplished by synthetic techniques which are known in the art.

To prepare derivatives of the monosaccharides, it is common to block or protect one or more of the hydroxyl groups with acetal blocking groups such as isopropylidene or cyclohexylidene groups and leave only one or two hydroxyl groups free to undergo further reaction. Various blocking groups and methods are described in U.S. Patent Nos. 2,715,121 and 4,056,322 and the disclosures of these patents are incorporated here by reference. For example, to prepare a derivative of α ,D-glucose which is blocked in its furanose ring structure, the 1,2- and 5,6-hydroxyl groups can be blocked using an isopropylidene blocking group and the 3-position left open to undergo further reaction. After the reaction to derivatize the 3-position is complete, the blocking groups may be selectively removed to allow for further derivatization at other positions if desired.

- 2 -

Various derivatives of monosaccharides, as well as synthetic methods for their preparation, are described in U.S. Patent Nos. Re. 30,354, Re. 30,379, Re. 32,268, 4,056,322, 4,735,934, 4,738,953, 4,996,195 and 5,010,058. The therapeutic activity of various monosaccharides and their derivatives is also disclosed in the above documents. The disclosures of these documents are incorporated here by reference.

Two well known derivatives of α ,D-glucose having beneficial therapeutic properties are amiprilose, 1,2-O-Isopropylidene-3-O-3'-(N, N'-dimethylamino-n-propyl)- α ,D-glucofuranose, and its hydrochloric acid salt, amiprilose HCl (THERAFECTIN®). These compounds are known to have anti-inflammatory activity and demonstrate utility in managing the signs and symptoms of rheumatoid arthritis. More generally, these compounds have activity as immunomodulators, and therefore have a therapeutic effect on other autoimmune disorders such as psoriasis, eczema or lupus.

Deoxy derivatives of 1,2-O-Isopropylidene- α ,D-glucofuranose are described in U.S. Patent No. 5,010,058. That patent describes methods of preparing deoxy derivatives of 1,2-O-Isopropylidene- α ,D-glucofuranose, and the use of such compounds in treating mammals with inflammatory and/or autoimmune disorders.

While some prior art monosaccharide derivatives have shown beneficial therapeutic activity, high doses of these monosaccharides may often be needed to be effective and produce the desired results. Because therapy for those inflammatory and autoimmune disorders is often chronic, there is a need to develop potent, nontoxic compounds which can be orally administered to promote ease of treatment and patient compliance.

An object of the present invention, therefore, is to provide new compounds that exhibit greater potency than available compounds.


Another object of the present invention is to provide a method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder.

Other objects and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objects and advantages of the invention may be realized and obtained by means of the compounds, pharmaceutical compositions and methods of treatment set out in the appended claims.

SUMMARY OF THE INVENTION

To achieve the above objects, and in accordance with the purpose of the invention as embodied and broadly described here, there is provided:

A pentose monosaccharide compound of the formula I:




wherein

R^1 is C_5 - C_{15} alkyl;


R^2 is a leaving group, NHR , $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$, or $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$, wherein R is C_3 - C_8 alkyl, C_3 - C_8 hydroxyalkyl, cyclohexyl- C_1 - C_5 -alkyl, phenyl- C_2 - C_5 -alkyl or pyridinyl- C_1 - C_5 -alkyl, Q is H , CH_3 , or C_2H_5 , and m is from 1-4 and p is from 0-4 or Q is OH and m and p are from 1-3, R' and R'' are each H or a lower alkyl group or, together

- 4 -

with the nitrogen atom carrying them, form a saturated heterocyclic substituent of the formula:




where X is CH₂, NH or O, and n ranges from 3-6,
or R² is a saturated heterocyclic ring of the formula:



where X is CH₂, NH or O, and n is from 3-6; and
R³ and R⁴ together form an acetal protecting group,
or a physiologically acceptable salt thereof.

A compound of formula II:




(II)

wherein


R⁵ is C₅-C₁₅ alkyl;

R⁶ is a leaving group, NHR, NH(CH₂)_mCH(Q)(CH₂)_pNR'R", or
O(CH₂)_mCH(Q)(CH₂)_pNR'R", wherein R is C₃-C₈ alkyl, C₃-C₈
hydroxyalkyl, cyclohexyl-C₁-C₅-alkyl, phenyl-C₂-C₅-alkyl or

pyridinyl- C_1-C_5 -alkyl, Q is H, CH_3 , or C_2H_5 , and m is from 1-4 and p is from 0-4 or Q is OH and m and p are from 1-3, R' and R'' are each H or a lower alkyl group or, together with the nitrogen atom carrying them, form a saturated heterocyclic substituent of the formula:



where X is CH_2 , NH or O, and n ranges from 3-6,
or R^6 is a saturated heterocyclic ring of the formula:



where X is CH_2 , NH or O, and n is from 3-6; and
 R^7 and R^8 together form an acetal protecting group,
or a physiologically acceptable salt thereof.


The anti-proliferative and/or anti-inflammatory compounds according to the invention exhibit beneficial therapeutic properties and are useful in the treatment of inflammatory and autoimmune disorders. Specifically, these compounds have demonstrated inhibitory effects on lymphocyte proliferation and immunomodulatory activity in art recognized *in vitro* screening tests. Compounds having this activity are useful for treating animals and humans with various dermatological and/or arthritic conditions such as psoriasis, atopic dermatitis, rheumatoid arthritis, osteoarthritis, scleroderma and systemic lupus erythematosus.

The present invention also provides pharmaceutical compositions containing the subject pentose monosaccharide compounds, and methods for the treatment of inflammatory and/or autoimmune disorders employing those compounds. The pharmaceutical compositions comprise an effective amount of at least one of the subject compounds or a physiologically acceptable salt thereof with a pharmaceutically acceptable carrier.

Advantageously, the compounds of the present invention exhibit greater potency, in terms of their activity, than other known monosaccharides.

DETAILED DESCRIPTION OF THE INVENTION


In one embodiment of the invention, the pentose monosaccharides are represented by formula I:



or physiologically acceptable salts thereof.

The substituent R^1 is a C_5 - C_{15} alkyl group. An alkyl group according to and throughout this invention includes both straight chain and branched alkyl groups. Preferred C_5 - C_{15} alkyl groups are heptyl, decyl, dodecyl, pentadecyl.

The substituent R^2 is a leaving group, NHR , $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$, $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$, or a saturated heterocyclic substituent of the formula:




As intermediates in the preparation of the anti-proliferative and/or anti-inflammatory compounds of formula I, R^2 can be a leaving group such as Br or an oxygen-containing leaving group (O-leaving group) such as p-methylbenzenesulfonate (tosylate), p-bromobenzenesulfonate (brosylate), p-nitrobenzenesulfonate (nosylate), methylsulfonate (mesylate), or trifluoromethylsulfonate (triflate). A preferred leaving group is p-methylbenzenesulfonate. These leaving group derivatized compounds can be prepared by means known in the art.

When R^2 is NHR, the substituent R is C_3 - C_8 alkyl, C_3 - C_8 hydroxyalkyl, cyclohexyl- C_1 - C_5 -alkyl, phenyl- C_2 - C_5 -alkyl or pyridinyl- C_1 - C_5 -alkyl. Preferred C_3 - C_8 alkyl groups are butyl, hexyl and heptyl. Preferred C_3 - C_8 hydroxyalkyl groups are hydroxypropyl and hydroxypentyl. A preferred cyclohexyl- C_1 - C_5 -alkyl group is methylcyclohexyl. A preferred phenyl- C_2 - C_5 -alkyl group is propylphenyl. A preferred pyridinyl- C_1 - C_5 -alkyl group is methylpyridinyl.


When R^2 is a $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$ or a $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$ group, Q is H, CH_3 , or C_2H_5 , and m is from 1-4 and p is from 0-4, or Q is OH and m and p are from 1-3. Preferably, when Q is H or CH_3 , m and p are 1 or 2 and when Q is OH, m and p are 1 or 2. Most preferably Q is H and m and p are 1. R' and R'' are each H or a lower (C_1 - C_6) alkyl group or, together with the nitrogen atom carrying them, form a saturated heterocyclic substituent of the formula:

- 8 -



where X is CH₂, NH or O; and n ranges from 3-6. R' and R" are preferably each selected from H, methyl, ethyl, propyl or isopropyl and of these, most preferably, R' and R" are both methyl. Where R' and R", together with the nitrogen carrying them, form a heterocyclic substituent, the preferred substituents are selected from a pyrrolidinyll ring, a piperidinyll ring, and a morpholinyl ring.

As indicated above, the substituent R² may also be a saturated heterocyclic ring of the formula:



where X is CH₂, NH or O; and n ranges from 3-6. Preferred heterocyclic rings are selected from a pyrrolidinyll ring, a piperidinyll ring, and a morpholinyl ring.

The substituents R³ and R⁴ together form an acetal protecting group. Preferred acetal protecting groups include an Isopropylidene group and cyclohexylidene group.

The pentose monosaccharides of formula I include xylose derivatives and ribose derivatives. The following are preferred anti-proliferative and/or anti-inflammatory compounds:

1,2-O-Isopropylidene-3-O-heptyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (Ia);

1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-aminoheptyl- α ,D-xylofuranose, (Ib);

1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (Ic);

1,2-O-Isopropylidene-3-O-dodecyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (Id);

1,2-O-Isopropylidene-3-O-dodecyl-5-deoxy-5-pyrrolidinyl- α ,D-xylofuranose, (Ie);

1,2-O-Isopropylidene-3-O-dodecyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (If);

1,2-O-Isopropylidene-3-O-decyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (Ig);

1,2-O-Isopropylidene-3-O-decyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (Ih);

1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-N-aminoethyl- α -D-xylofuranose, (Ii);

1,2-O-Isopropylidene-3-O-pentadecyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose, (Ij);

1,2-O-Isopropylidene-3-O-pentadecyl-5-deoxy-5-aminopropylphenyl- α ,D-xylofuranose, (Ik);


1,2-O-Isopropylidene-3-O-decyl-5-O-2'-(N',N'-Diisopropylaminoethyl)- α ,D-xylofuranose, (Il);

1,2-O-Isopropylidene-3-O-decyl-5-O-3'-(N'-piperidinylpropyl)- α ,D-xylofuranose, (Im); and

1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-pyrrolidinyl- α ,D-xylofuranose, (In).

Particularly preferred compounds are compounds (Ia) and (Ih).

A second embodiment of this invention are pentose monosaccharide compounds of formula II:




(II)

- 10 -

or physiologically acceptable salts thereof.

The substituent R^5 is C_5-C_{15} alkyl. R^5 has the same preferred embodiments as described above for R^1 in formula I.

The substituent R^6 is a leaving group, NHR , $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$, $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$, or a saturated heterocyclic substituent of the formula:




As intermediates in the preparation of the anti-proliferative and/or anti-inflammatory compounds of formula II, R^6 can be a leaving group such as Br or an oxygen-containing leaving group (O-leaving group) such as p-methylbenzenesulfonate (tosylate), p-bromobenzenesulfonate (brosylate), p-nitrobenzenesulfonate (nosylate), methylsulfonate (mesylate), or trifluoromethylsulfonate (triflate). A preferred leaving group is p-methylbenzenesulfonate. These leaving group derivatized compounds can be prepared by means known in the art.

When R^6 is NHR , the substituent R is C_3-C_8 alkyl, C_3-C_8 hydroxyalkyl, cyclohexyl- C_1-C_5 -alkyl, phenyl- C_2-C_5 -alkyl or pyridinyl- C_1-C_5 -alkyl. Preferred C_3-C_8 alkyl groups are butyl, hexyl and heptyl. Preferred C_3-C_8 hydroxyalkyl groups are hydroxypropyl and hydroxypentyl. A preferred cyclohexyl- C_1-C_5 -alkyl group is methylcyclohexyl. A preferred phenyl- C_2-C_5 -alkyl group is propylphenyl. A preferred pyridinyl- C_1-C_5 -alkyl group is methylpyridinyl.

When R^6 is a $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$ or a $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$ group, Q is H, CH_3 , or C_2H_5 , and m is from 1-4 and p is from 0-4 or Q is OH and m and p are from 1-3. Preferably when Q is H or CH_3 , m and p are 1 or 2 and


- 11 -

when Q is OH, m and p are 1-2. Most preferably Q is H and m and p are 1. R' and R" are each H or a lower (C₁-C₆) alkyl group or, together with the nitrogen atom carrying them, form a saturated heterocyclic substituent of the formula:



where X is CH₂, NH or O; and n ranges from 3-6. R' and R" are preferably each selected from H, methyl, ethyl, propyl or isopropyl and of these, most preferably, R' and R" are both methyl. Where R' and R", together with the nitrogen carrying them, form a heterocyclic substituent, the preferred substituents are selected from a pyrrolidinyl ring, a piperidinyl ring, and a morpholinyl ring.

The substituent R⁶ may also be a saturated heterocyclic ring of the formula:



where X is CH₂, NH or O; and n ranges from 3-6. Preferred heterocyclic rings are selected from a pyrrolidinyl ring, a piperidinyl ring, and a morpholinyl ring.

The substituents R⁷ and R⁸ together form an acetal protecting group, preferably an isopropylidene or a cyclohexylidene group.

The pentose monosaccharides of formula II are derivatives of the monosaccharide lyxose and include both α and β isomers. The following compounds are preferred:

Undecyl 2,3-O-Isopropylidene-5-deoxy-5-pyrrolidinyl-α,β-lyxofuranose, (IIa); and

Undecyl 2,3-O-Isopropylidene-5-deoxy-5-aminobutyl- α , β -lyxofuranose, (IIb).

The anti-proliferative and/or anti-inflammatory compounds of the present invention also include the physiologically acceptable salts of the compounds of formulas I and II. Preferred physiologically acceptable salts are acid-addition salts. Common physiologically acceptable acid-addition salts are hydrochloric acid salts, oxalate salts and tartrate salts.

The compounds of the invention may be prepared according to the following general synthetic procedure. A suitably protected hexofuranose having a single free hydroxyl group is alkylated at that hydroxyl group using a base and an appropriate alkyl halide. Selective removal of a protecting group yields a 1,2-diol functionality which can be oxidatively cleaved to yield an alkylated pentofuranose derivative. Upon treatment of this pentofuranose derivative with a reducing agent a new pentofuranose is obtained that contains a free hydroxyl group. The free hydroxyl group can be alkylated with an appropriate alkyl halide and a base to give compounds of the present invention. Alternatively, the free hydroxyl group can also be derivatized to form a suitable leaving group such as tosylate and then the leaving group of the resulting derivative displaced with an amine to yield the deoxy, N-substituted compounds of the present invention. The examples below demonstrate this procedure, as well as the specific preparation, for compounds according to this invention. The examples are illustrative, and are not intended to limit, in any manner, the claimed invention.

Pharmacologic Activity

Compounds of the present invention have demonstrated immunomodulatory and anti-proliferative effects in biological assays. Standard *in vitro* immunologic assays were performed on compounds of the present invention in order to assess

- 13 -

anti-proliferative and immunomodulatory activity. These included the mixed lymphocyte response (MLR), and the mouse spleen cell mitogen induced blastogenesis assay. The MLR functions as a test of immunomodulatory effects of the compounds whereby inhibitory effects on T lymphocyte activation and antigen presentation are determined. Anti-proliferative effects were demonstrated by measuring the inhibitory effects of compounds of present invention on the cellular proliferation of Concanavalin A stimulated murine splenocytes. Because inflammation and mechanisms involved in the pathogenesis of autoimmune diseases involve cellular activation and proliferation as well as abnormal immune system activation, these assays are appropriate to use as screens for novel compounds in the treatment of inflammatory and/or autoimmune disorders.

Compounds of the present invention demonstrated anti-proliferative and immunomodulatory activities. Concentrations tested ranged from 3 to 300 micromolar. With strong activity defined as half maximal inhibitory concentrations of less than 30 micromolar, compounds of the present invention uniformly demonstrated strong *in vitro* anti-proliferative effects. Similarly, compounds of this invention were also found to be strong immunomodulators. These results indicate that compounds of the present invention are extremely highly active agents with potent *in vitro* activities.

Pentose monosaccharide derivatives according to the present invention are useful for treating animals and mammals with inflammatory and/or autoimmune disorders such as psoriasis, atopic dermatitis, rheumatoid arthritis, osteoarthritis, scleroderma and systemic lupus erythematosus. Due to their valuable pharmacological properties, compounds of the present invention or their physiologically acceptable salts are particularly suitable for use as active compounds

in pharmaceutical compositions for the treatment of, for example, rheumatic inflammatory disorders.

The anti-proliferative and/or anti-inflammatory compounds can either be administered alone in the form of microcapsules, in mixtures with one another or in combination with acceptable pharmaceutical carriers. The invention, thus, also relates to pharmaceutical compositions which comprise an effective amount of at least one compound of the present invention with or without a pharmaceutically and physiologically acceptable carrier. If appropriate, the compound may be administered in the form of a physiologically acceptable salt, for example, an acid-addition salt.

The present invention also encompasses a method of treating animals or humans suffering from inflammatory and/or autoimmune disorders which comprises administering to the animal or person an effective amount of at least one of the compounds of the invention, or an acid-addition salt thereof, with or without a pharmaceutically acceptable carrier. The compounds according to the invention can be administered orally, topically, rectally, anterally, internally, by boluses or, if desired, parenterally; oral administration is preferred.

Suitable solid or liquid galenic formulations are, for example, granules, powders, coated tablets, microcapsules, suppositories, syrups, elixirs, suspensions, emulsions, drops or injectable solutions. Also, compounds of the invention may be employed in preparations having a protracted release of the active compound. Commonly used additives in protracted release preparations are excipients, disintegrates, binders, coating agents, swelling agents, glidants, or lubricants, flavors, sweeteners or solubilizers. More specifically, frequently used additives are, for example, magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, lactalbumin, gelatin, starch, cellulose and its derivatives, animal and vegetable

- 15 -

oils, polyethylene glycols and solvents. The solvents include sterile water and monohydric or polyhydric alcohols such as glycerol.

The pharmaceutical compositions are preferably produced and administered in dosage units, each unit containing as an active component an effective dose of at least one compound of the present invention and/or at least one of its physiologically acceptable salts. In the case of mammals, the effective dose to treat autoimmune and/or anti-inflammatory disorders can range from about 1 to 100 mg per kilogram of body weight per day.

EXAMPLES

NMR spectra were recorded on a Varian XL-300 MHz using TMS as the internal standard reference. FTIR spectra were recorded on a Nicolet MX-1 instrument using KBr plates. Optical rotation was measured on a Perkin-Elmer Model 241 polarimeter. CIMS were obtained with a Finnigan MAT 4510 mass spectrometer with an INCOS data system. Generally, a direct exposure probe was used and ammonia or methane was used as a reagent gas (0.35 mm Hg, 120°C source temperature).

Example 1.

1,2-O-Isopropylidene-3-O-heptyl-5-pyrrolidinyl
-5-deoxy- α , \underline{D} -xylofuranose.

Step 1: Preparation of 1,2-O-Isopropylidene-3-O-heptyl- α , \underline{D} -glucofuranose.

The general procedure for the synthesis of 1,2-O-Isopropylidene-3-O-alkyl- α , \underline{D} -glucofuranose (alkyl = C_7H_{15}) has been described in U.S. Patent No. 5,010,058.

- 16 -

Step 2: Preparation of 1,2-O-Isopropylidene-3-O-heptyl- α ,D-xylofuranose.

1,2-O-Isopropylidene-3-O-heptyl- α ,D-glucofuranose from step 1 (31.8g) was dissolved in 60ml of aqueous p-dioxane (50% v/v) at ambient temperature. To this was added dropwise an aqueous solution of sodium periodate (21.4g in 175ml). After 1.5 hours the reaction was judged to be complete by tlc. The solvent was removed under reduced pressure with mild heating. The solid obtained was triturated with dichloromethane (3x150ml), the dichloromethane solutions were combined, dried over MgSO_4 , filtered and concentrated. The oil obtained (28.0g, 97%) was used without further purification.

The oil obtained above (28g) was dissolved in aqueous ethanol (500ml, 75% v/v) at ambient temperature. To this was added dropwise an ethanolic solution of sodium borohydride (14.0g in 200ml). After 1 hour, the reaction was judged to be complete by tlc and the solvent was removed under reduced pressure. The resulting slurry was extracted with dichloromethane (3x200ml). The combined extracts were dried over MgSO_4 , filtered, and concentrated. The crude product was chromatographed on silica gel (25% diethyl ether in hexanes) to give the desired 1,2-O-Isopropylidene-3-O-heptyl- α ,D-xylofuranose in 92% overall yield.

Step 3: Preparation of 1,2-O-Isopropylidene-3-O-heptyl-5-O-p-tosyl- α ,D-xylofuranose.

To a solution of 1,2-O-Isopropylidene-3-O-heptyl- α ,D-xylofuranose from step 2 (22.0g) in pyridine (30ml) was added a solution of tosylchloride (17.4g) in pyridine (20ml). The reaction mixture was stirred at room temperature and the reaction's progress monitored by tlc. After 4 hours the

- 17 -

reaction mixture was concentrated, dissolved in ether, washed with aqueous sodium bicarbonate then water, dried over MgSO_4 , filtered and concentrated. The crude material obtained was chromatographed on silica gel (10% diethyl ether in hexanes) to give 1,2-O-Isopropylidene-3-O-heptyl-5-O-p-tosyl- α , β -xylofuranose (28.8g).

Step 4: Preparation of 1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-pyrrolidinyl- α , β -xylofuranose.

A mixture of 1,2-O-Isopropylidene-3-O-heptyl-5-O-p-tosyl- α , β -xylofuranose from step 3 (3.3g) and pyrrolidine (3.0g) was heated at 70-80 °C. After 1.5 hours the excess pyrrolidine was removed under reduced pressure. The residue was dissolved in diethyl ether and washed with a saturated sodium bicarbonate solution, a saturated brine solution, dried over MgSO_4 , filtered and concentrated. The crude material thus obtained was chromatographed on silica gel (30% diethyl ether in hexanes) to give 1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-pyrrolidinyl- α , β -xylofuranose (2.0g).

Other 3-O-alkyl derivatives such as decyl, dodecyl, pentadecyl, and derivatives were prepared according to the above procedure. The starting materials for step 1 were prepared by substituting an appropriate alkylhalide for the 1-bromoheptane employed in U.S. Patent No. 5,010,058. Other 5-deoxy, 5-N derivatives were prepared by substituting an appropriate amine or diamine for pyrrolidine.

Example 2.

1,2-O-Isopropylidene-3-O-heptyl-5-O-Dimethylaminopropyl- α , β -xylofuranose.

This material was prepared by treating 1,2-O-Isopropylidene-3-O-heptyl- α , \underline{D} -xylofuranose (Example 1, Step 2) with powdered sodium hydroxide and dimethylaminopropyl chloride according to the procedure in Example 3, Step 1 of U.S. Patent No. 5,010,058. The title compound was obtained in 59% yield after chromatography on silica gel (5% diethyl ether in hexanes to 100% diethyl ether). Other 3-O-alkyl derivatives such as decyl, dodecyl, and pentadecyl derivatives were prepared by substituting an appropriate alkylhalide for the 1-bromoheptane employed here. Other 5-O derivatives were prepared by substituting an appropriate aminoalkyl halide for the dimethylaminopropyl chloride.

Example 3.

Undecyl 2,3-O-Isopropylidene-5-deoxy-5-pyrrolidinyl- α , \underline{D} -lyxofuranose.

Step 1: Preparation of Undecyl 2,3:5,6-O-DiIsopropylidene- α , \underline{D} -Mannofuranoside.

Sodium hydride (2.2g) was added to a solution of 2,3:5,6-Di-O-Isopropylidene- α , \underline{D} -mannofuranose (20g) and undecyl bromide (21g) in anhydrous DMF (50ml). The reaction mixture was warmed to 35°C until tlc indicated no presence of starting material. The reaction was quenched by the addition of methanol (20ml) and then water (10ml). The reaction mixture was concentrated under reduced pressure and the residue obtained dissolved in diethylether. The ether solution was washed with water (2x50ml) and saturated sodium chloride solution (30ml), dried over MgSO_4 , filtered and concentrated. The crude material thus obtained was purified by silica gel chromatography (10% ether in hexanes) to give the title compound (14.0g).

Step 2: Preparation of Undecyl 2,3-O-Isopropylidene- α ,D-mannofuranoside.

To a solution of undecyl 2,3:5,6-O-diisopropylidene- α ,D-mannofuranoside (11.5g) in THF (12ml), cooled to 5°C in an ice-water bath, was added dropwise a 30% HClO₄ solution (11.5ml). The reaction mixture was stirred and monitored by tlc. After 2 hrs a further 10ml of 30% HClO₄ was added. Upon complete consumption of the starting material, as judged by tlc, the reaction mixture was quenched with a saturated aqueous K₂CO₃ solution, filtered and concentrated under reduced pressure. The residue obtained was dissolved in diethylether, dried over MgSO₄, filtered, concentrated and chromatographed on silica gel with 1:1 ether - hexanes to give the title compound (4g).

Step 3: Preparation of Undecyl 2,3-O-Isopropylidene- α ,D-lyxofuranoside.

To a 1:1 dioxane/water (10ml) solution of Undecyl 2,3-O-Isopropylidene- α ,D-mannofuranoside (5g) was added an aqueous solution of sodium periodate (2.9g dissolved in 60ml H₂O). After stirring 4 hrs at room temperature the reaction was judged to be complete by tlc. The reaction mixture was concentrated under reduced pressure and the residue obtained triturated three times with dichloromethane. The organic fractions were combined, dried over MgSO₄, filtered and concentrated. The material obtained was carried forward without further purification.

The material obtained above (3.9g) was dissolved in 75% ethanol in water (80ml). To this was added, dropwise, a solution of sodium borohydride (2.6g) in ethanol (70ml). The reaction mixture was stirred at room temperature for approximately 4 hrs at which time there was no trace of starting material by tlc. The solvent was removed under

- 20 -

reduced pressure, and the resulting slurry extracted with dichloromethane. The dichloromethane extracts were combined, dried over MgSO_4 , filtered and concentrated. The crude product obtained was chromatographed on silica gel (30% diethyl ether in hexane) to give the title compound (2g).

Step 4: Preparation of Undecyl 2,3-O-Isopropylidene-5-deoxy-5-pyrrolidinyl- α ,D-lyxofuranoside.


To a solution of undecyl 2,3-O-Isopropylidene- α ,D-lyxofuranoside (2g) in pyridine (5ml) was added tosylchloride (1.4g) dissolved in pyridine (5ml). The resulting mixture was stirred at room temperature and the reaction monitored by tlc. Upon disappearance of starting material the reaction mixture was concentrated, dissolved in ether, washed with aqueous solution bicarbonate then with water, dried over MgSO_4 , filtered and concentrated. The crude material obtained was chromatographed on silica gel (10% diethyl ether in hexanes) to give undecyl 2,3-O-Isopropylidene-5-p-tosyl- α ,D-lyxofuranoside.

A mixture of undecyl 1,2-O-Isopropylidene-5-p-tosyl- α ,D-lyxofuranoside (1.0g) and pyrrolidine (5ml) was heated at 75°C for 1 hr. The reaction mixture was concentrated under reduced pressure and the crude obtained was chromatographed on silica gel (diethyl ether as eluent). Undecyl 2,3-O-Isopropylidene-5-deoxy- 5-pyrrolidinyl- α ,D-lyxofuranose was obtained as a pale yellow oil (0.5g).

Other glycosides such as decyl were prepared by substituting decyl bromide for the undecyl bromide employed in the preparation of undecyl 2,3-O-Isopropylidene- α ,D-mannofuranose. Additional compounds can be prepared by similarly substituting an appropriate C_5 - C_{15} alkyl halide for the undecyl bromide and/or by substituting an appropriate amine or diamine for pyrrolidine.

The claimed invention is:


1. A pentose monosaccharide compound of the formula I:



wherein


R^1 is C_5-C_{15} alkyl;

R^2 is NHR , $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$, or $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$, wherein R is C_3-C_8 alkyl, C_3-C_8 hydroxyalkyl, cyclohexyl- C_1-C_5 -alkyl, phenyl- C_2-C_5 -alkyl or pyridinyl- C_1-C_5 -alkyl, Q is H , CH_3 , or C_2H_5 , and m is from 1-4 and p is from 0-4 or Q is OH and m and p are from 1-3, R' and R'' are each H or a lower alkyl group or, together with the nitrogen atom carrying them, form a saturated heterocyclic substituent of the formula:



where X is CH_2 , NH or O , and n ranges from 3-6,

or R^2 is a saturated heterocyclic ring of the formula:



where X is CH₂, NH or O, and n is from 3-6; and
 R³ and R⁴ together form an acetal protecting group,
 or a physiologically acceptable salt thereof.


2. The compound of claim 1, wherein

R¹ is heptyl, decyl, dodecyl, pentadecyl,

R² is NHR, wherein R is butyl, hexyl, heptyl,
 hydroxypropyl and hydroxypentyl;

NH(CH₂)_mCH(Q)(CH₂)_pNR'R", or
 O(CH₂)_mCH(Q)(CH₂)_pNR'R", wherein Q is H, or CH₃ and m and p
 are 1 or 2 or Q is OH and m and p are 1 or 2, R' and R" are
 each selected from H, methyl, ethyl, propyl or isopropyl, or
 where R' and R", together with the nitrogen carrying them,
 form a heterocycle selected from a pyrrolidinyl ring; a
 piperidinyl ring, and a morpholinyl ring; or

said saturated heterocyclic substituent of the
 formula:



is selected from a pyrrolidinyl ring, a piperidinyl ring, and
 a morpholinyl ring; and

R³ and R⁴ form an acetal protecting group selected from
 an isopropylidene group and a cyclohexylidene group,
 or a physiologically acceptable salt thereof.

3. The compound of claim 2, wherein said compound is a
 xylose derivative.

4. The compound of claim 3, wherein said compound is
 selected from

1,2-O-Isopropylidene-3-O-heptyl-5-O-3'-(N',N'-
 dimethylaminopropyl)- α ,D-xylofuranose,

1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-aminoheptyl-
 α ,D-xylofuranose,

1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-dodecyl-5-O-3'-(N',N'-dimethylaminopropyl)- α -D-xylofuranose,
1,2-O-Isopropylidene-3-O-dodecyl-5-deoxy-5-pyrrolidinyl- α -D-xylofuranose,
1,2-O-Isopropylidene-3-O-dodecyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-decyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-decyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-N-aminoethyl- α -D-xylofuranose,
1,2-O-Isopropylidene-3-O-pentadecyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-pentadecyl-5-deoxy-5-aminopropylphenyl- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-decyl-5-O-2'-(N',N'-Diisopropylaminoethyl)- α ,D-xylofuranose,
1,2-O-Isopropylidene-3-O-decyl-5-O-3'-(N'-piperidinylpropyl)- α ,D-xylofuranose, and
1,2-O-Isopropylidene-3-O-heptyl-5-deoxy-5-pyrrolidinyl- α ,D-xylofuranose.

5. The compound of claim 2 wherein said compound is 1,2-O-Isopropylidene-3-O-heptyl-5-O-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose.

6. The compound of claim 2 wherein said compound is 1,2-O-Isopropylidene-3-O-decyl-5-deoxy-5-N-3'-(N',N'-dimethylaminopropyl)- α ,D-xylofuranose.

7. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

8. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 1.

9. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.

10. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 2.


11. A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.

12. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 5.

13. A pharmaceutical composition comprising a compound according to claim 6 and a pharmaceutically acceptable carrier.

14. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 6.


15. A compound of formula II:



wherein


R^5 is C_5-C_{15} alkyl;

R^6 is NHR , $NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$, or $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$, wherein R is C_3-C_8 alkyl, C_3-C_8 hydroxyalkyl, cyclohexyl- C_1-C_5 -alkyl, phenyl- C_2-C_5 -alkyl or pyridinyl- C_1-C_5 -alkyl, Q is H , CH_3 , or C_2H_5 , and m is from 1-4 and p is from 0-4 or Q is OH and m and p are from 1-3, R' and R'' are each H or a lower alkyl group or, together with the nitrogen atom carrying them, form a saturated heterocyclic substituent of the formula:



where X is CH_2 , NH or O , and n ranges from 3-6, or

R^6 is a saturated heterocyclic ring of the formula:




where X is CH_2 , NH or O , and n is from 3-6; and

R^7 and R^8 together form an acetal protecting group, or a physiologically acceptable salt thereof.

16. The compound of claim 15, wherein
 R^5 is heptyl, decyl, dodecyl, pentadecyl,
 R^6 is NHR, wherein R is butyl, hexyl, heptyl,
 hydroxypropyl and hydroxypentyl;

$NH(CH_2)_mCH(Q)(CH_2)_pNR'R''$, or
 $O(CH_2)_mCH(Q)(CH_2)_pNR'R''$, wherein Q is H, or CH_3 , and m and p
 are 1 or 2 or Q is OH and m and p are 1 or 2, R' and R'' are
 each selected from H, methyl, ethyl, propyl or isopropyl, or
 where R' and R'' , together with the nitrogen carrying them,
 form a heterocycle selected from a pyrrolidinyl ring, a
 piperidinyl ring, and a morpholinyl ring;

or said saturated heterocyclic substituent of the
 formula:



is selected from a pyrrolidinyl ring, a piperidinyl ring, and
 a morpholinyl ring; and

R^7 and R^8 form an acetal protecting group selected from
 an isopropylidene group and a cyclohexylidene group,
 or a physiologically acceptable salt thereof.

17. The compound of claim 16 wherein said compound is
 Undecyl 2,3-O-Isopropylidene-5-deoxy-5-pyrrolidinyl- α , \underline{D} -
 lyxofuranose.

18. The compound of claim 16 wherein said compound is
 Undecyl 2,3-O-Isopropylidene-5-deoxy-5-aminobutyl- α , \underline{D} -
 lyxofuranose.

19. A pharmaceutical composition comprising a compound
 according to claim 15 and a pharmaceutically acceptable
 carrier.

20. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 15.

21. A pharmaceutical composition comprising a compound according to claim 16 and a pharmaceutically acceptable carrier.

22. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 16.

23. A pharmaceutical composition comprising a compound according to claim 17 and a pharmaceutically acceptable carrier.


24. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 17.

25. A pharmaceutical composition comprising a compound according to claim 18 and a pharmaceutically acceptable carrier.

26. A method of treating an animal or human suffering from an inflammatory and/or autoimmune disorder comprising administering thereto an amount effective to treat an inflammatory and/or autoimmune disorder of the compound according to claim 18.

27. A pentose monosaccharide compound of the formula I:

- 28 -



wherein

R^1 is C_5 - C_{15} alkyl;


R^2 is a leaving group, and

R^3 and R^4 together form an acetal protecting group.

28. The compound of claim 27 wherein R^2 is an O-leaving group moiety selected from p-methylbenzenesulfonate, p-bromobenzenesulfonate, p-nitrobenzenesulfonate, methylsulfonate, and trifluoromethylsulfonate.

29. The compound of claim 28 wherein R^2 is p-methylbenzenesulfonate.

30. A compound of formula II:



wherein

R^5 is C_5 - C_{15} alkyl,

R^6 is a leaving group, and

R^7 and R^8 together form an acetal protecting group.

31. The compound of claim 30 wherein R^6 is an O-leaving group moiety selected from p-methylbenzenesulfonate, p-bromobenzenesulfonate, p-nitrobenzenesulfonate, methylsulfonate, trifluoromethylsulfonate.

32. The compound of claim 31 wherein R⁶ is p-methylbenzenesulfonate.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 93/10134

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C07H15/12 C07H19/044 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07H A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,92 04359 (GREENWICH PHARMACEUTICALS) 19 March 1992 see claims 1,4,8,19,20,25 ---	1,7,15, 19
Y	US,A,4 735 934 (P. GORDON) 5 April 1988 cited in the application see claims 1-4 ---	1,7,15, 19
Y	EP,A,0 404 136 (GREENWICH PHARMACEUTICALS) 27 December 1990 see claims 1,16 & US-A-5010058 cited in the application ---	1,7,15, 19
P,Y	WO,A,93 13117 (GREENWICH PHARMACEUTICALS) 8 July 1993 see claims 10,40 -----	1,7,15, 19

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

28 January 1994

Date of mailing of the international search report

18. 02. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Brennan, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/10134

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
"Remark: Although claims 8, 12, 14, 20, 22, 24, 26 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition."
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 93/10134

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9204359	19-03-92	AU-A- 8622991	30-03-92
		CA-A- 2091587	13-03-92
		EP-A- 0548226	30-06-93
US-A-4735934	05-04-88	US-A- 4738953	19-04-88
EP-A-0404136	27-12-90	US-A- 5010058	23-04-91
		AU-A- 5769190	03-01-91
		CA-A- 2019705	22-12-90
		JP-A- 3163091	15-07-91
WO-A-9313117	08-07-93	AU-B- 3249593	28-07-93